# SLFN14

## Overview
SLFN14 is a gene that encodes the protein schlafen family member 14, which is a member of the Schlafen protein family. This protein functions primarily as an endoribonuclease, playing a critical role in the degradation of ribosomal RNA (rRNA) and ribosome-associated mRNA, which is essential for ribosome turnover and cellular homeostasis (Fletcher2018Role). SLFN14 is characterized by distinct structural domains, including an N-domain with endoribonuclease activity, an M-domain for ribosome interaction, and a C-domain with putative helicase/ATPase activity (Jo2022Structural). The protein is involved in various cellular processes, including translation control and platelet formation, and is distributed throughout the nucleus and cytoplasm (Fletcher2018Role). Mutations in the SLFN14 gene have been linked to inherited thrombocytopenias, such as Platelet-type bleeding disorder 20, underscoring its clinical significance in platelet physiology and bleeding disorders (Fletcher2015SLFN14; Polokhov2023Novel).

## Structure
The SLFN14 protein is part of the schlafen family and is characterized by distinct structural domains. It contains an N-domain with endoribonuclease activity, an M-domain that acts as a linker and protein-interacting domain, and a C-domain that is a putative helicase/ATPase domain (Jo2022Structural). The N-domain features a conserved active site with a U-shaped architecture for nucleotide binding, essential for its role in cleaving rRNA and ribosome-associated mRNA in a Mg2+ and Mn2+ dependent manner (Jo2022Structural). The M-domain is involved in ribosome binding, and alterations in this domain can reduce RNA cleavage activity (Jo2022Structural). The C-domain is homologous to superfamily I RNA/DNA helicases, and SLFN14's M-domain is notably longer with a different connection to its C-domain compared to other Group III SLFNs (Jo2022Structural).

SLFN14 also contains a zinc finger motif, which may assist in nucleotide recognition or protein folding (Jo2022Structural). Mutations in the ATPase-AAA-4 domain, such as K218E, K219N, and V220D, have been linked to impaired platelet function and are associated with thrombocytopenia (Fletcher2015SLFN14). These mutations can lead to decreased protein expression due to partial misfolding and post-translational degradation (Fletcher2018Role).

## Function
The SLFN14 gene encodes a protein that functions as an endoribonuclease, playing a critical role in the degradation of ribosomal RNA (rRNA) and ribosome-associated mRNA in healthy human cells. This activity is essential for ribosome degradation and is particularly observed in megakaryocyte-related cell lines, which are precursors to platelets (Fletcher2018Role). SLFN14 is part of the Schlafen protein family, which is involved in T-cell development, differentiation, and immune response (Fletcher2018Role).

In the cellular context, SLFN14 associates with ribosomes and individual ribosomal subunits, leading to the endoribonucleolytic cleavage of rRNA. This process is crucial for maintaining normal cellular function and is implicated in the regulation of translation control (Fletcher2018Role). The protein is distributed throughout the nucleus and cytoplasm, indicating its involvement in ribosomal function and stability (Fletcher2018Role).

SLFN14's activity is also linked to its role in platelet formation and maturation, as it is specifically expressed during the maturation of blood cell types with minimal RNA content, such as platelets and erythrocytes (Fletcher2018Role). Mutations in SLFN14 can lead to thrombocytopenia, a condition characterized by low platelet counts and excessive bleeding, highlighting its importance in normal platelet physiology (Fletcher2015SLFN14).

## Clinical Significance
Mutations in the SLFN14 gene are associated with inherited thrombocytopenias, particularly a condition known as Platelet-type bleeding disorder 20 (BDPLT20). This disorder is characterized by macrothrombocytopenia, which involves a low platelet count and enlarged platelets, leading to excessive bleeding and platelet secretion defects (Fletcher2015SLFN14; Polokhov2023Novel). Patients with SLFN14 mutations often exhibit moderate thrombocytopenia, reduced platelet aggregation, and decreased ATP secretion, contributing to a bleeding phenotype (Fletcher2015SLFN14; Nurden2020Inherited).

The SLFN14 gene mutations, such as K218E, K219N, and V220D, are located in the ATPase-AAA-4 domain and are associated with a dominant inheritance pattern (Fletcher2015SLFN14). These mutations lead to reduced SLFN14 protein expression due to partial misfolding and post-translational degradation, resulting in platelet dysfunction (Fletcher2018Role). The mutations also cause a decrease in the number of dense granules in platelets, further impairing platelet function (Fletcher2015SLFN14).

A novel mutation, p.K219E, has been identified in a patient with severe hemorrhagic syndrome, highlighting the clinical significance of SLFN14 in platelet-related disorders (Polokhov2023Novel). These findings underscore the importance of SLFN14 in maintaining normal platelet function and its role in bleeding disorders when mutated.

## Interactions
SLFN14 is a ribosome-associated endoribonuclease that interacts with ribosomal RNA, tRNA, and mRNA, facilitating their degradation. This interaction is crucial for its role in regulating gene expression, particularly in the context of viral infections such as HIV-1. SLFN14 preferentially affects the expression of transcripts rich in rare codons, such as the HIV-1 Gag protein, by degrading ribosomal RNA and causing ribosome stalling during translation elongation (Valenzuela2023Schlafen14).

The protein's endoribonuclease activity is essential for its function, as demonstrated by the inability of a mutant SLFN14 lacking this activity to inhibit HIV-1 expression effectively (Valenzuela2023Schlafen14). SLFN14's interaction with ribosomes is confirmed by its cytoplasmic localization and association with ribosomal components, as shown through sedimentation analysis (Valenzuela2023Schlafen14).

SLFN14 also interacts with nucleic acids in a manner dependent on its structural domains. The N-domain exhibits endoribonuclease activity, while the M-domain is crucial for ribosome interaction, suggesting it may serve as a docking site for nucleic acids or functional cofactors (Jo2022Structural). These interactions are vital for understanding SLFN14's role in cellular processes and its potential impact on viral replication and platelet function.


## References


[1. (Jo2022Structural) Ukhyun Jo and Yves Pommier. Structural, molecular, and functional insights into schlafen proteins. Experimental &amp; Molecular Medicine, 54(6):730–738, June 2022. URL: http://dx.doi.org/10.1038/s12276-022-00794-0, doi:10.1038/s12276-022-00794-0. This article has 30 citations.](https://doi.org/10.1038/s12276-022-00794-0)

2. (Valenzuela2023Schlafen14) Schlafen14 Regulates Gene Expression Depending on Codon Usage. This article has 0 citations.

[3. (Fletcher2018Role) Sarah J. Fletcher, Vera P. Pisareva, Abdullah O. Khan, Andrew Tcherepanov, Neil V. Morgan, and Andrey V. Pisarev. Role of the novel endoribonuclease slfn14 and its disease-causing mutations in ribosomal degradation. RNA, 24(7):939–949, April 2018. URL: http://dx.doi.org/10.1261/rna.066415.118, doi:10.1261/rna.066415.118. This article has 13 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1261/rna.066415.118)

[4. (Nurden2020Inherited) Alan T. Nurden and Paquita Nurden. Inherited thrombocytopenias: history, advances and perspectives. Haematologica, 105(8):2004–2019, June 2020. URL: http://dx.doi.org/10.3324/haematol.2019.233197, doi:10.3324/haematol.2019.233197. This article has 47 citations.](https://doi.org/10.3324/haematol.2019.233197)

[5. (Polokhov2023Novel) Dmitrii Polokhov, Daria Fedorova, Anastasiya Ignatova, Evgeniya Ponomarenko, Elena Rashevskaya, Alexey Martyanov, Nadezhda Podoplelova, Maxim Aleksenko, Irina Mersiyanova, Elena Seregina, Aleksandr Poletaev, Ekaterina Truchina, Elena Raykina, Svetlana Plyasunova, Galina Novichkova, Pavel Zharkov, and Mikhail Panteleev. Novel slfn14 mutation associated with macrothrombocytopenia in a patient with severe haemorrhagic syndrome. Orphanet Journal of Rare Diseases, April 2023. URL: http://dx.doi.org/10.1186/s13023-023-02675-9, doi:10.1186/s13023-023-02675-9. This article has 1 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s13023-023-02675-9)

[6. (Fletcher2015SLFN14) Sarah J. Fletcher, Ben Johnson, Gillian C. Lowe, Danai Bem, Sian Drake, Marie Lordkipanidzé, Isabel Sánchez Guiú, Ban Dawood, José Rivera, Michael A. Simpson, Martina E. Daly, Jayashree Motwani, Peter W. Collins, Steve P. Watson, and Neil V. Morgan. Slfn14 mutations underlie thrombocytopenia with excessive bleeding and platelet secretion defects. Journal of Clinical Investigation, 125(9):3600–3605, August 2015. URL: http://dx.doi.org/10.1172/jci80347, doi:10.1172/jci80347. This article has 67 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1172/jci80347)